“Pharma Focus: Introducing Biosimilars Successfully”, was hosted by CSafe Global at a recent workshop attended by over 120 of the top delegates from the Korean biopharmaceutical manufacturing and logistics service sector.
Partner case studies were presented illustrating how CSafe continues to extend South Korean biosimilar manufacturers effective and safe door-to-door delivery of products. The subject of GDP regulations and how they apply globally, particularly in relation qualification of supply chain partners, was covered as well.
A representative from the largest developer of biosimilar monoclonal antibodies (mAbs) and biopharmaceuticals in Asia gave a presentation addressing best practices in supply chain qualifications. The presentation was well received and resulted in a 60 minute Q & A covering a wide range of topics including packaging techniques, data collection and air cargo labeling regulations.
President and CEO of CSafe Global, Brian Kohr, spoke about the company’s support of the South Korean industry sector and its expected growth to 150 billion Won ($130m). CSafe will provide product in the region through an enhanced local service facility.